{"protocolSection":{"identificationModule":{"nctId":"NCT00596271","orgStudyIdInfo":{"id":"IC51-308"},"organization":{"fullName":"Valneva Austria GmbH","class":"INDUSTRY"},"briefTitle":"Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440","officialTitle":"Safety and Immunogenicity of Concomitant Vaccination With IC51 and HARVIX® 1440 in Healthy Subjects. A Single-blind Randomized, Controlled Phase 3 Study"},"statusModule":{"statusVerifiedDate":"2014-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2005-09"},"primaryCompletionDateStruct":{"date":"2006-07","type":"ACTUAL"},"completionDateStruct":{"date":"2008-08","type":"ACTUAL"},"studyFirstSubmitDate":"2008-01-04","studyFirstSubmitQcDate":"2008-01-15","studyFirstPostDateStruct":{"date":"2008-01-16","type":"ESTIMATED"},"resultsFirstSubmitDate":"2013-11-12","resultsFirstSubmitQcDate":"2014-04-09","resultsFirstPostDateStruct":{"date":"2014-05-13","type":"ESTIMATED"},"lastUpdateSubmitDate":"2014-04-09","lastUpdatePostDateStruct":{"date":"2014-05-13","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Valneva Austria GmbH","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The objective is to investigate the immunogenicity of the Japanese Encephalitis vaccine IC51 (JE-PIV) single and concomitant with HAVRIX® 1440","detailedDescription":"This is a randomized, controlled, multi-center, single-blind phase 3 study. The study population consists of male and female healthy subjects, aged at least 18 years.\n\n192 subjects will be enrolled at 2 sites in Europe."},"conditionsModule":{"conditions":["Japanese Encephalitis"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"SINGLE","whoMasked":["PARTICIPANT"]}},"enrollmentInfo":{"count":192,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"IC51 and Placebo","type":"ACTIVE_COMPARATOR","description":"6 mcg i.m. IC51 with 2 injections (day 0 and 28)and placebo 0.5 mL with 1 injection (day 0)","interventionNames":["Biological: IC51","Other: Placebo"]},{"label":"HAVRIX and placebo","type":"ACTIVE_COMPARATOR","description":"HAVRIX with 1 injection (day 0) and placebo 0.5 mL with 2 injections (day 0 and 28)","interventionNames":["Biological: HAVRIX","Other: Placebo"]},{"label":"IC51 and HAVRIX","type":"ACTIVE_COMPARATOR","description":"IC51 6 mcg i.m. with 2 injections (day 0 and 28) and HAVRIX with 1 injection (day 0)","interventionNames":["Biological: IC51","Biological: HAVRIX"]}],"interventions":[{"type":"BIOLOGICAL","name":"IC51","armGroupLabels":["IC51 and HAVRIX","IC51 and Placebo"],"otherNames":["Japanese Encephalitis purified inactivated vaccine"]},{"type":"BIOLOGICAL","name":"HAVRIX","armGroupLabels":["HAVRIX and placebo","IC51 and HAVRIX"]},{"type":"OTHER","name":"Placebo","armGroupLabels":["HAVRIX and placebo","IC51 and Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Geometric Mean Titer (GMT) at Day 56 for Anti-JEV Neutralizing Antibodies","description":"anti-JEV Neutralizing Antibodies were tabulated for IC51 groups only; for HAV GMTs (co-primary endpoint GMT for Hepatitis A Virus (HAV) Antibody at Day 28), please refer to \"Outcome 2\" within outcome measure section","timeFrame":"Day 56"},{"measure":"GMT for Hepatitis A Virus (HAV) Antibody at Day 28","timeFrame":"Day 28"}],"secondaryOutcomes":[{"measure":"Seroconversion Rate (SCR) at Day 56 for Plaque Reduction Neutralization Assay (PRNT) and HAV at Day 28","timeFrame":"day 28 and 56"},{"measure":"GMT and SCR for PRNT at Day 28 and HAV at Day 56","timeFrame":"day 28 and 56"},{"measure":"Safety","description":"Rate of Adverse Events (AEs), Serious Adverse Events (SAEs) and medically attended AEs, local and systemic tolerability, changes in safety laboratory parameters (hematology, serum chemistry, urinalysis)","timeFrame":"until 6 month after last vaccination"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* At least 18 years of age\n* In female subjects either childbearing potential terminated by surgery or one year post-menopausal, or a negative serum pregnancy test during screening and the willingness not to become pregnant during the study period and 30 days after the last vaccination by practicing reliable methods of contraception\n* Written informed consent obtained prior to study entry\n\nExclusion Criteria:\n\n* History of clinical manifestation of any flavivirus infection\n* History of vaccination against Japanese encephalitis (JE), Yellow fever and Dengue fever (an anti-JEV neutralizing antibody titer \\>= 1:10 at baseline is acceptable for inclusion, these subjects will be part of the safety population, but will not be analyzed for immunogenicity in the per-protocol analysis)\n* History of any previous Hepatitis A vaccination and infection\n* Use of any other investigational or non-registered drug or vaccine in addition to the study vaccine during the study period or within 30 days preceding the first dose of study vaccine\n* Planned administration of another vaccine during the study period\n* Immunodeficiency including post-organ-transplantation or immunosuppressive therapy\n* A family history of congenital or hereditary immunodeficiency\n* History of autoimmune disease\n* Administration of chronic (defined as more than 14 days) immunosuppressants or other immune-modifying drugs within six months of vaccination.\n* Any acute infections within 4 weeks prior to enrollment\n* Infection with human immunodeficiency virus (HIV), Hepatitis B (HBsAg) or Hepatitis C","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Astrid Kaltenboeck, Ph.D.","affiliation":"Valneva Austria GmbH","role":"STUDY_DIRECTOR"}]}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"First Subject In: 26.09.2005, Last Subject Out: 14.07.2006 performed at centers for travelling medicine/vaccinology","groups":[{"id":"FG000","title":"IC51 and Placebo","description":"6 mcg i.m. IC51 with 2 injections (day 0 and 28)and placebo 0.5 mL with 1 injection (day 0)"},{"id":"FG001","title":"HAVRIX and Placebo","description":"HAVRIX with 1 injection (day 0) and placebo 0.5 mL with 2 injections (day 0 and 28)"},{"id":"FG002","title":"IC51 and HAVRIX","description":"IC51 6 mcg i.m. with 2 injections (day 0 and 28) and HAVRIX with 1 injection (day 0)"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"65"},{"groupId":"FG001","numSubjects":"65"},{"groupId":"FG002","numSubjects":"62"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"60"},{"groupId":"FG001","numSubjects":"59"},{"groupId":"FG002","numSubjects":"61"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"IC51 and Placebo","description":"6 mcg i.m. IC51 with 2 injections (day 0 and 28)and placebo 0.5 mL with 1 injection (day 0)"},{"id":"BG001","title":"HAVRIX and Placebo","description":"HAVRIX with 1 injection (day 0) and placebo 0.5 mL with 2 injections (day 0 and 28)"},{"id":"BG002","title":"IC51 and HAVRIX","description":"IC51 6 mcg i.m. with 2 injections (day 0 and 28) and HAVRIX with 1 injection (day 0)"},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"65"},{"groupId":"BG001","value":"65"},{"groupId":"BG002","value":"62"},{"groupId":"BG003","value":"192"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"65"},{"groupId":"BG001","value":"65"},{"groupId":"BG002","value":"62"},{"groupId":"BG003","value":"192"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"34"},{"groupId":"BG003","value":"103"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"28"},{"groupId":"BG003","value":"89"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Europe","categories":[{"measurements":[{"groupId":"BG000","value":"65"},{"groupId":"BG001","value":"65"},{"groupId":"BG002","value":"62"},{"groupId":"BG003","value":"192"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Titer (GMT) at Day 56 for Anti-JEV Neutralizing Antibodies","description":"anti-JEV Neutralizing Antibodies were tabulated for IC51 groups only; for HAV GMTs (co-primary endpoint GMT for Hepatitis A Virus (HAV) Antibody at Day 28), please refer to \"Outcome 2\" within outcome measure section","populationDescription":"Per Protocol Population includes all randomized subjects without major protocol deviations","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titers","timeFrame":"Day 56","groups":[{"id":"OG000","title":"IC51 and Placebo"},{"id":"OG001","title":"IC51 and HAVRIX"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"58"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"192.2","lowerLimit":"147.9","upperLimit":"249.8"},{"groupId":"OG001","value":"202.7","lowerLimit":"153.7","upperLimit":"261.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The primary efficacy analysis will compare the IC51+HAVRIX vs. IC51+Placebo group in terms of the GMT for anti- JEV neutralizing antibody at day 56. An observed cases approach will be applied for the primary analysis","testedNonInferiority":true,"nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"Non-inferiority of the combined administration is postulated, if the lower bounds of both twosided 95% confidence intervals for the GMT ratios (of combined vaccination over single vaccination) are \\> 1/2.\n\nThis procedure is equivalent to the approach based on a 1-sided test with a significance level of 2.5% for each comparison with the null hypothesis H0 : ratio ≤ 0.5 versus the alternative hypotheses H1 : ratio \\> 0.5.","pValue":"<0.0001","statisticalMethod":"ANOVA","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Seroconversion Rate (SCR) at Day 56 for Plaque Reduction Neutralization Assay (PRNT) and HAV at Day 28","reportingStatus":"NOT_POSTED","timeFrame":"day 28 and 56"},{"type":"SECONDARY","title":"GMT and SCR for PRNT at Day 28 and HAV at Day 56","reportingStatus":"NOT_POSTED","timeFrame":"day 28 and 56"},{"type":"SECONDARY","title":"Safety","description":"Rate of Adverse Events (AEs), Serious Adverse Events (SAEs) and medically attended AEs, local and systemic tolerability, changes in safety laboratory parameters (hematology, serum chemistry, urinalysis)","reportingStatus":"NOT_POSTED","timeFrame":"until 6 month after last vaccination"},{"type":"PRIMARY","title":"GMT for Hepatitis A Virus (HAV) Antibody at Day 28","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titers","timeFrame":"Day 28","groups":[{"id":"OG000","title":"HAVRIX + Placebo"},{"id":"OG001","title":"IC51 + HAVRIX"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"58"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.7","lowerLimit":"17.2","upperLimit":"27.5"},{"groupId":"OG001","value":"24","lowerLimit":"19.1","upperLimit":"30.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The primary efficacy analysis will compare the IC51+HAVRIX vs. HAVRIX+Placebo group in terms of the GMT for HAV antibody at day 28. An observed cases approach will be applied for the primary analysis.","testedNonInferiority":true,"nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"Non-inferiority of the combined administration is postulated, if the lower bounds of both twosided 95% confidence intervals for the GMT ratios (of combined vaccination over single vaccination) are \\> 1/2.\n\nThis procedure is equivalent to the approach based on a 1-sided test with a significance level of 2.5% for each comparison with the null hypothesis H0 : ratio ≤ 0.5 versus the alternative hypotheses H1 : ratio \\> 0.5.","pValue":"<0.0001","statisticalMethod":"ANOVA","ciPctValue":"95"}]}]},"adverseEventsModule":{"frequencyThreshold":"2","eventGroups":[{"id":"EG000","title":"IC51 and Placebo","description":"6 mcg i.m. IC51 with 2 injections (day 0 and 28)and placebo 0.5 mL with 1 injection (day 0)","seriousNumAffected":1,"seriousNumAtRisk":65,"otherNumAffected":27,"otherNumAtRisk":65},{"id":"EG001","title":"HAVRIX and Placebo","description":"HAVRIX with 1 injection (day 0) and placebo 0.5 mL with 2 injections (day 0 and 28)","seriousNumAffected":0,"seriousNumAtRisk":65,"otherNumAffected":31,"otherNumAtRisk":65},{"id":"EG002","title":"IC51 and HAVRIX","description":"IC51 6 mcg i.m. with 2 injections (day 0 and 28) and HAVRIX with 1 injection (day 0)","seriousNumAffected":0,"seriousNumAtRisk":62,"otherNumAffected":24,"otherNumAtRisk":62}],"seriousEvents":[{"term":"Convulsion","organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":62}]}],"otherEvents":[{"term":"Fatique","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":65},{"groupId":"EG001","numAffected":5,"numAtRisk":65},{"groupId":"EG002","numAffected":5,"numAtRisk":62}]},{"term":"Influenza like illness","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":65},{"groupId":"EG001","numAffected":3,"numAtRisk":65},{"groupId":"EG002","numAffected":3,"numAtRisk":62}]},{"term":"Pyrexia","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":65},{"groupId":"EG001","numAffected":0,"numAtRisk":65},{"groupId":"EG002","numAffected":2,"numAtRisk":62}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":65},{"groupId":"EG001","numAffected":4,"numAtRisk":65},{"groupId":"EG002","numAffected":5,"numAtRisk":62}]},{"term":"Cystitis","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":65},{"groupId":"EG001","numAffected":1,"numAtRisk":65},{"groupId":"EG002","numAffected":2,"numAtRisk":62}]},{"term":"Rhinitis","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":65},{"groupId":"EG001","numAffected":0,"numAtRisk":65},{"groupId":"EG002","numAffected":2,"numAtRisk":62}]},{"term":"Bronchitis","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":65},{"groupId":"EG001","numAffected":0,"numAtRisk":65},{"groupId":"EG002","numAffected":2,"numAtRisk":62}]},{"term":"Gastrointeritis","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":65},{"groupId":"EG001","numAffected":1,"numAtRisk":65},{"groupId":"EG002","numAffected":2,"numAtRisk":62}]},{"term":"Rash pustular","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":65},{"groupId":"EG001","numAffected":2,"numAtRisk":65},{"groupId":"EG002","numAffected":0,"numAtRisk":62}]},{"term":"Headache","organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":65},{"groupId":"EG001","numAffected":10,"numAtRisk":65},{"groupId":"EG002","numAffected":4,"numAtRisk":62}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":65},{"groupId":"EG001","numAffected":1,"numAtRisk":65},{"groupId":"EG002","numAffected":4,"numAtRisk":62}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":65},{"groupId":"EG001","numAffected":2,"numAtRisk":65},{"groupId":"EG002","numAffected":2,"numAtRisk":62}]},{"term":"Hepatic enzyme increased","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":65},{"groupId":"EG001","numAffected":1,"numAtRisk":65},{"groupId":"EG002","numAffected":0,"numAtRisk":62}]},{"term":"Pharyngolaryngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":65},{"groupId":"EG001","numAffected":2,"numAtRisk":65},{"groupId":"EG002","numAffected":0,"numAtRisk":62}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":65},{"groupId":"EG001","numAffected":1,"numAtRisk":65},{"groupId":"EG002","numAffected":2,"numAtRisk":62}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":65},{"groupId":"EG001","numAffected":1,"numAtRisk":65},{"groupId":"EG002","numAffected":2,"numAtRisk":62}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"pointOfContact":{"title":"Katrin Dubischar-Kastner","organization":"Valneva Austria GmbH","email":"info@valneva.com","phone":"+43 1 206 20","phoneExt":"0"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D004672","term":"Encephalitis, Japanese"}],"ancestors":[{"id":"D004671","term":"Encephalitis, Arbovirus"},{"id":"D018792","term":"Encephalitis, Viral"},{"id":"D020805","term":"Central Nervous System Viral Diseases"},{"id":"D002494","term":"Central Nervous System Infections"},{"id":"D007239","term":"Infections"},{"id":"D000069544","term":"Infectious Encephalitis"},{"id":"D001102","term":"Arbovirus Infections"},{"id":"D000079426","term":"Vector Borne Diseases"},{"id":"D000096724","term":"Mosquito-Borne Diseases"},{"id":"D014777","term":"Virus Diseases"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D018177","term":"Flavivirus Infections"},{"id":"D018178","term":"Flaviviridae Infections"},{"id":"D004660","term":"Encephalitis"},{"id":"D001927","term":"Brain Diseases"},{"id":"D002493","term":"Central Nervous System Diseases"},{"id":"D009422","term":"Nervous System Diseases"},{"id":"D000090862","term":"Neuroinflammatory Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D022362","term":"Hepatitis A Vaccines"}],"ancestors":[{"id":"D014761","term":"Viral Hepatitis Vaccines"},{"id":"D014765","term":"Viral Vaccines"},{"id":"D014612","term":"Vaccines"},{"id":"D001688","term":"Biological Products"},{"id":"D045424","term":"Complex Mixtures"}]}},"hasResults":true}